Wednesday, June 17, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Op Ed states Healthcare is Infrastructure

President Biden’s sweeping infrastructure proposal, the American Jobs Plan, is the legislation that launched a thousand gripes.

From the day it was introduced, the package spawned not only the expected debates about its cost and how to pay for it, but also a charged debate about what should and should not be classified as “infrastructure.”

The disagreement over what constitutes infrastructure is particularly perplexing considering that we generally know what we mean when we talk about infrastructure in other contexts. For example, when we speak of a company having strong infrastructure, we know what that means, and it’s rare that we’re talking only about buildings and pipes.

We typically talk about people, process and technology—the necessary building blocks for the company’s financial success.

But when we talk about infrastructure in the American Jobs Plan, beyond roads and bridges, opinions diverge about investments in clean water, broadband, and especially investment in essential healthcare.

Source: Fierce Healthcare

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!